
==== Front
Wien Klin Wochenschr
Wien. Klin. Wochenschr
Wiener Klinische Wochenschrift
0043-5325 1613-7671 Springer Vienna Vienna 

1694
10.1007/s00508-020-01694-x
Clinical-Pathological Conference
Clinical-Pathological Conference Series from the Medical University of Graz
Case No 171: A 37-year-old engineer with bolus hold-up (esophageal food impaction)Fabian Elisabeth MD, PhD, MSc, BSc1 Gröchenig Hans Peter MD2 Bauer Philipp K. MD3 Eherer Andreas J. MD4 Gugatschka Markus MD5 Binder Lukas MD4 Langner Cord MD6 Fickert Peter MD4 Krejs Guenter J. MD, AGAF, marc88@example.net 4 1 grid.22937.3d0000 0000 9259 8492Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria 
2 grid.490543.f0000 0001 0124 884XDepartment of Internal Medicine, Hospital Brothers of St. John of God, Sankt Veit an der Glan, Austria 
3 grid.22937.3d0000 0000 9259 8492Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria 
4 grid.11598.340000 0000 8988 2476Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria 
5 grid.11598.340000 0000 8988 2476Division of Phoniatrics, Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria 
6 grid.11598.340000 0000 8988 2476Department of Pathology, Medical University of Graz, Graz, Austria 
29 6 2020 
29 6 2020 
2020 
404-910-1670
© The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Keywords
DysphagiaEosinophilic esophagitisBudesonideProton pump inhibitorsMedical University of GrazOpen access funding provided by Medical University of Graz.

issue-copyright-statement© Springer-Verlag GmbH Austria, part of Springer Nature 2020
==== Body
Presentation of case
Dr. L. Binder:
The patient is a technical engineer working for a large international company. Except for recurrent episodes of dysphagia over the last 3 years, his history is unremarkable. He reports that "ingested food gets stuck behind his chest bone about once a month". Originally from Brno, Czech Republic, he has been living in France for the past several years where he has been treated for dysphagia by otorhinolaryngologists who prescribed prokinetics, a proton pump inhibitor (PPI) and neuroleptics; however, these medications did not improve his dysphagia. Finishing a meal would take him about twice as long as his wife. After moving to Graz, Austria 3 months ago, he again experienced a bolus hold-up (a piece of meat got stuck in his esophagus). Used to being treated by otorhinolaryngologists, the patient came to the emergency room of the Department for Otorhinolaryngology of this institution where the bolus was removed with the patient under general anesthesia using a rigid esophagoscope. The investigation also showed a questionable stenosis of the proximal esophagus with marked vulnerability of the mucosa. The patient was told that surgery might become necessary if esophageal injury or perforation has occurred, and he was admitted for observation. The physical examination was otherwise unremarkable and all routine laboratory parameters were within normal limits.

A diagnostic test was performed.

Differential diagnosis
Dr. H.P. Gröchenig:
The patient under discussion is a young man with a history of dysphagia and recurrent food impaction, which may be due to a stenosis of the esophagus with remarkably increased vulnerability of the mucosa seen on endoscopy. Prokinetics, PPIs and neuroleptic drugs did not improve his condition. Dysphagia is defined as a sensation of sticking or obstruction of the passage of food through the mouth, pharynx or esophagus and should be distinguished from other symptoms, such as aphagia and odynophagia. Aphagia is the complete esophageal obstruction, which is usually due to bolus impaction and represents a medical emergency. Odynophagia means pain on swallowing and frequently occurs together with dysphagia [1]. The prevalence of any type of dysphagia in the general population is very high and amounts to about 20%. It affects more often women and older persons than men and younger people [2]. The differential diagnosis in patients with dysphagia is broad and involves a variety of underlying mechanisms and conditions (Table 1). Dysphagia can be categorized by location, i.e. oropharyngeal (or transfer) dysphagia and esophageal dysphagia, and by cause. Determination of whether the problem is associated with difficulty transporting oral contents through the pharynx into the esophagus or within the esophagus is crucial for the diagnostic evaluation. Dysphagia caused by a large bolus or luminal narrowing is called mechanical dysphagia, whereas dysphagia due to weakness of peristaltic contractions or due to impaired deglutitive inhibition causing nonperistaltic contractions and impaired sphincter relaxation is termed motor dysphagia [1]. A detailed history and an awareness of potential diagnoses are useful in identifying true esophageal dysphagia. Indeed, oropharyngeal dysphagia can be distinguished from esophageal dysphagia with 80% accuracy if there is (1) delay in initiating the swallow, (2) deglutitive postnasal regurgitation, (3) deglutitive coughing and (4) repetitive swallowing needed to achieve satisfactory clearance [3, 4]. Since these symptoms are not reported in the discussed patient, oropharyngeal dysphagia can most likely be ruled out as the cause of his problem.Table 1 Differential diagnoses of dysphagia [1]

	Oropharyngeal dysphagia	Esophageal dysphagia	
Propulsive	Neurogenic

Cerebral vascular accident

Parkinson's disease

Amyotrophic lateral sclerosis

Brainstem tumor 

Guillain-Barré syndrome

Huntington's chorea

Post-polio syndrome

Multiple sclerosis

Cerebral palsy

	Myogenic

Myasthenia gravis

Polymyositis

Mixed connective tissue disease

Oculopharyngeal muscular dystrophy

Paraneoplastic syndrome

Myotonic dystrophy

Sarcoidosis

	Dysphagia for solids and liquids	
GERD with weak peristalsis

Achalasia (primary and secondary)

Diffuse esophageal spasm

Scleroderma

	
Structural	Zenker's diverticulum

Neoplasm

Cervical web

Cricopharyngeal bar

Osteophytes

Congenital abnormalities

Post head and neck surgery

Chemotherapy mucositis

Radiation

Corrosive injury

Infection

	Dysphagia for solids	
Intermittent

Schatzki ring

Esophageal web

Progressive

Neoplasm

Variable

Peptic stricture

Eosinophilic esophagitis

Hiatal hernia

Extrinsic compression

Surgical stenosis

Radiation esophagitis

Ringed esophagus

Congenital esophageal stenosis

	Odynophagia

Pill esophagitis

Infectious esophagitis

Caustic injury

Chemotherapy

Sclerotherapy

Crohn's disease

Behçet's disease

Bullous pemphigoid

Lichen planus

	
GERD gastroesophageal reflux disease



For identification of potential causes of esophageal dysphagia, a focused history should be taken. In particular it is important to distinguish whether (1) dysphagia is experienced when swallowing solids and liquids or with solids alone, (2) it is progressive or (3) there are other associated symptoms such as pain on swallowing or regurgitation [2]. This will help identify an obstructive or functional cause of dysphagia. Motor disorders such as achalasia and esophagogastric junction outflow obstruction, and major disorders of peristalsis such as absent contractility, distal esophageal spasm and hypercontractile esophagus (jackhammer) are typically associated with bolus hold-up causing dysphagia. Minor motility disorders such as ineffective esophageal motility and fragmented peristalsis are, however, of uncertain importance in dysphagia [5, 6]. The discussed patient reported intermittent bolus hold-up events when swallowing solid food without progression of symptoms or weight loss over time; swallowing liquids does not cause problems. The following three essential diagnostic work-up modalities are available: (1) esophagoscopy with esophageal biopsies to exclude fibrous strictures, reflux esophagitis and eosinophilic esophagitis, (2) barium swallow, preferably as cineradiography, to exclude subtle strictures missed on endoscopy and to observe bolus progression, and (3) esophageal manometry to detect motor disorders. In the case of negative endoscopy and unremarkable manometry, the diagnosis of functional dysphagia, which is caused by factors such as medication (opioids and other motility-altering drugs [7]), gastroesophageal reflux, sensitization of the peripheral nerves or central processing abnormalities (including psychological factors) has to be considered [2]. In view of the patient's history, some specific differential diagnoses should be discussed:

With a prevalence of 10–20% in the western world, gastroesophageal reflux disease (GERD) is the most common gastrointestinal diagnosis reported during visits to outpatient clinics [8]. Clinically, heartburn and regurgitation are the leading symptoms in GERD, but also extraesophageal manifestations such as chronic cough, asthma, laryngitis and other airway symptoms as well as atypical symptoms such as dyspepsia, epigastric pain, nausea, bloating and belching may be present (Table 2). With respect to the esophagus, the spectrum of injury includes esophagitis, stricture, the development of columnar metaplasia (Barrett's esophagus) and adenocarcinoma [9]. GERD is more frequently linked to dysphagia than any other cause [10]. Although dysphagia can be associated with uncomplicated GERD, its presence warrants investigation for potential complications such as underlying motility disorder, peptic stricture, narrow Schatzki ring, or malignancy [11]. In patients with excessive reflux of acid and pepsin, injury of the surface layers of esophageal mucosa and consequently erosive esophagitis will occur [9]. The severity of esophagitis has been shown to be even more important than the actual peptic stricture diameter in generating symptoms of dysphagia [12]. The diagnosis of GERD is made based on a particular constellation of symptoms, endoscopic findings, pH-metry, and response to acid-suppressive therapy. Barium radiographs, routine biopsies and esophageal manometry have no role in the diagnosis of GERD [13].Table 2 Symptoms associated with gastroesophageal reflux disease (GERD) [9]

Esophageal symptoms	Extraesophageal symptoms	
Common symptoms:

Heartburn

Regurgitation

Dysphagia

Chest pain

	Chronic cough	
Laryngitis (hoarseness, throat clearing)	
Asthma (reflux as a cofactor leading to poorly controlled disease)	
Erosion of dental enamel	
Proposed associations:

Pharyngitis

Sinusitis

Recurrent otitis media

Idiopathic pulmonary fibrosis

	
Less common symptoms:

Odynophagia

Water brash

Subxiphoidal pain

Nausea

	


In clinical practice, dysphagia is also frequently associated with the administration of certain drugs including doxycycline, tetracycline, bisphosphonates, iron preparations and nonsteroidal anti-inflammatory drugs, which can directly damage the esophageal mucosa. This condition is termed pill esophagitis. It is often accompanied by odynophagia, i.e. the sensation of retrosternal pain as the bolus passes [14, 15] and is found in younger patients. However, pill esophagitis typically does not induce intermittent symptoms and is usually not responsible for food impaction as reported in the discussed patient.

Indeed, the most common diagnosis in young patients who present with dysphagia for predominantly solid food, recurrent food impaction and chest pain is eosinophilic esophagitis. It is a chronic and abnormal Th2-type immune response characterized by intense eosinophilic inflammation in the esophageal epithelium, leading to esophageal dysfunction, remodeling of the esophageal wall accompanied by subepithelial fibrosis [16], and subsequent esophageal dysmotility [17]. The prevalence of this disease has been increasing over the past decades and is estimated to be 23 per 100,000 in North American and European populations [18]. Eosinophilic esophagitis has been reported in all ages, but is predominantly found in young men aged 20–40 years and in children [19] who often present with a history of atopy including asthma, allergic rhinitis, atopic dermatitis and immunoglobulin (Ig) E‑mediated food allergy [20]. The most common symptoms in the affected adults are dysphagia, reported by 25–100% of patients, and food impaction, found in 33–50% of patients [21]. The diagnosis of eosinophilic esophagitis is often delayed since about 30% of patients may experience some benefit from PPIs. Eosinophilic esophagitis must be differentiated from secondary eosinophilia and eosinophilic gastroenteritis involving the entire gastrointestinal tract [16]. On endoscopy, linear furrows, concentric rings (trachealization, ringed esophagus, cat esophagus), white exudates, decreased capillary vasculature in the esophageal mucosa, esophageal strictures and a narrow-caliber esophagus are characteristic, but not specific findings in eosinophilic esophagitis [22]. For histological proof of eosinophilic esophagitis, more than 15 eosinophils per high-power field (HPF) in the epithelium are required [23]. The management of eosinophilic esophagitis consists of swallowed topical corticosteroids, particularly budesonide. Empirical elimination diets are another effective therapeutic approach and should be tried. Esophageal dilatation of strictures that persist after drug therapies and diet may be necessary [20].

Another differential diagnosis that should be considered in a young patient with dysphagia is achalasia. Achalasia is a rare primary motility disorder of the esophagus caused by the loss of nitric oxide and vasoactive intestinal polypeptide releasing inhibitory interneurons in the myenteric plexus that are involved in facilitating lower esophageal sphincter (LES) relaxation for gastric accommodation of food boluses [24–26]. This results in aperistalsis in the tubular esophagus and impaired relaxation of the LES [27]. The pathogenesis of achalasia is not yet fully understood. Loss of the inhibitory innervation of the esophagus can be due to extrinsic (including central nervous lesions involving the dorsal motor nucleus or the vagal fibres) or intrinsic causes, i.e. loss of the inhibitory ganglion cells in the myenteric plexus due to inflammation with subsequent progressive destruction of the myenteric ganglion cells and neural fibrosis [28]. Degeneration of inhibitory postganglionic neurons of the esophagus and LES due to inflammation [29, 30] may eventually lead to impaired relaxation of the LES and hypercontractility of the distal esophagus [31]. Typical symptoms of achalasia include dysphagia for solids and liquids in up to 100% [32–34], regurgitation of undigested food, chest pain [35], weight loss and nocturnal cough [32] as well as belching due to alterations of the upper esophageal belch reflex [36], and hiccups [37]. Dyspepsia and the sensation of heartburn which is reported by 72% of affected patients [38] often lead to a misdiagnosis of GERD [39]. For the diagnosis of achalasia, barium esophagogram and endoscopy are mandatory in addition to manometry. By definition, the manometric finding of aperistalsis and incomplete LES relaxation without evidence of mechanical obstruction solidifies the diagnosis of achalasia [40]. The incidence of achalasia is 1 in 100,000 individuals per year with a peak between 30 and 60 years of age; the prevalence is about 10 per 100,000 population [41–43]. In view of all of the above, I do not think that this patient's presentation speaks for the diagnosis of achalasia. In rare cases, achalasia may be mimicked by cancer (pseudoachalasia), which we have recently described in a very young patient [44]. However, the long history of dysphagia without symptom progression speaks against this diagnosis.

Rarely, dysphagia found in younger patients may be caused by congenital abnormalities of the aortic arch such as double aortic arch, right or cervical aortic arch, Kommerell's diverticulum, an aberrant right subclavian artery (arteria lusoria) or pulmonary artery sling. On barium swallow, the bayonet sign is typical for dysphagia aortica or dysphagia lusoria. In the case of suspected abnormal vascular anatomy, CT angiography will confirm the diagnosis [45].

However, the particular constellation of factors in this patient, namely the history, his age, the intermittent episodes of dysphagia and food impaction, and the fact that he did not respond to PPI therapy strongly suggests the diagnosis of eosinophilic esophagitis. Thus, esophageal biopsies would help establish an unequivocal diagnosis.

Dr. H.P. Gröchenig's diagnosis
Eosinophilic esophagitis



Discussion of case
Dr. M. Gugatschka:
When the discussed patient came to the emergency room, the diagnosis of food impaction was confirmed by esophagogram (Fig. 1). After the bolus had been removed by means of a rigid esophagoscope, the patient had a normal barium swallow without signs of achalasia.Fig. 1 Images from a barium swallow (cineesophagogram) with a complete hold-up of barium in the proximal esophagus and b free passage of barium into the stomach after removal of the bolus, without evidence of perforation



Dr. A.J. Eherer:
Manometry revealed a slightly prolonged duration of swallowing with minimal nonspecific alterations, probably due to mild esophageal spasm. On endoscopy, multiple areas of the esophagus appeared like crepe paper with thickened mucosa, there were white plaques, longitudinal furrows and minimal circular rings (Fig. 2). Biopsies were taken from multiple sites in the distal 10 cm of esophagus.Fig. 2 Esophagoscopy shows white plaques (arrows) and a laceration (L) with sloughed-off mucosa and some bleeding. Discrete circular rings (R) are also visible



Dr. C. Langner:
Histology of the esophageal biopsies revealed eosinophilic esophagitis (Fig. 3), which is a chronic, clinically and histologically defined, inflammatory condition of the esophagus that should be differentiated from other diseases that cause or potentially contribute to esophageal eosinophilia (Table 3), such as GERD, hypereosinophilic syndrome, Crohn's disease, celiac disease, connective tissue disease, achalasia, drugs and infection. Of these, GERD is considered to be the most common cause of secondary esophageal eosinophilia in clinical practice [47–50]. The histological hallmark of eosinophilic esophagitis is a marked, often patchy infiltration of the esophageal epithelium with more than 15 eosinophils per HPF. Qualitatively, the eosinophilic distribution is diffuse throughout the epithelium without superficial or basal predominance. Furthermore, eosinophil degranulation, aggregates of 5–10 eosinophils, eosinophilic surface layering with microabscesses (visible as white plaques on endoscopy), basal zone hyperplasia, papillary elongation, dilated intercellular spaces, and increased eosinophils in stroma with fibrosis of the lamina propria may be present [23, 51, 52]. Due to the marked variability in the eosinophil counts in both per biopsy and per HPF counts, multiple biopsies from different locations need to be obtained to confirm the diagnosis [52]. Characteristic endoscopic findings such as furrows and exudates are associated with a higher peak eosinophil count and should therefore be targeted; macroscopically normal mucosa shows the lowest eosinophil counts [53]. For this reason, current guidelines recommend that at least six biopsies be taken from different locations, focusing on areas with endoscopic mucosal abnormalities [23].Fig. 3 The esophageal biopsy shows an increased number of eosinophils (>15 per high-power field, HPF) between squamous epithelial cells. There is also basal zone hyperplasia and dilatation of intercellular spaces, i.e. spongiosis (original × 200, hematoxylin & eosin stain)

Table 3 Conditions associated with esophageal eosinophilia [46]

Eosinophilic esophagitis	
Eosinophilic gastritis, gastroenteritis, or colitis with esophageal involvement	
Gastroesophageal reflux disease	
Achalasia and other disorders of esophageal dysmotility	
Hypereosinophilic syndrome	
Crohn's disease with esophageal involvement	
Infections (fungal, viral)	
Connective tissue disorders	
Hypermotility syndromes	
Autoimmune disorders and vasculitides	
Dermatologic conditions with esophageal involvement (i.e. pemphigus)	
Drug hypersensitivity reactions	
Pill esophagitis	
Graft vs. host disease	
Mendelian disorders (Marfan syndrome type II, hyper-IgE syndrome, PTEN-hamartoma tumor syndrome, Netherton's syndrome, severe atopy metabolic wasting syndrome)	
PTEN



Dr. L. Binder:
The human esophagus is lined by a stratified squamous epithelium that is devoid of eosinophils under normal conditions [52]. The pathogenesis of eosinophilic esophagitis is not completely understood, but it is suggested that an enhanced Th2-type immune reaction against causal food allergens, with or without a potential trigger by aeroallergens, is the main underlying mechanism [54, 55]. This reaction occurs primarily via non-IgE-mediated hypersensitivity. When esophageal epithelium is exposed to causal allergens, they will permeate the subepithelium and trigger the activation of dendritic cells through the induction of thymic stromal lymphopoietin (TSLP) [56]. Activated dendritic cells then strongly induce the proliferation of Th2 cells, which leads to an increase in cytokines associated with eosinophilic inflammation [54]. These include interleukin (IL)-5, which differentiates and recruits intramedullary eosinophils or those in the peripheral intravascular compartment [57], and IL-13 and IL-15, which induce secretion of eotaxin‑3 from epithelial cells, one of the strongest chemotactic factors for eosinophils [58]. In addition, IL-13 decreases the barrier function of the squamous epithelium by decreasing gene expression of the epidermal differentiation complex [59]. In conjunction with mast cells, aggregated and activated eosinophils produce transforming growth factor(TGF)-β1. Together with activated fibroblasts and periostin this subsequently leads to fibrotic changes in the esophageal wall and dysfunction of the smooth muscles. Due to the finding of single nucleotide polymorphisms in genes encoding eotaxin‑3, TGF-β1, filaggrin, TSLP and TSLP receptor, a genetic susceptibility to eosinophilic esophagitis is suggested [54].

Clinical symptoms of eosinophilic esophagitis differ between children and adults. Children primarily present with nonspecific symptoms such as heartburn, nausea, vomiting, abdominal pain or failure to thrive in addition to dysphagia. Since the disease progresses over time with subsequent fibrostenotic changes of the esophageal wall, adults mostly complain of eating difficulties, repeated dysphagia and food impaction [60]. Prolonged mastication, ample use of liquids to wash down solids, and prolonged time to finish a meal are consequences frequently found in patients with eosinophilic esophagitis [20]. The acronym IMPACT summarizes adaptive behaviors related to longstanding dysphagia: Imbibe fluid with meals, Modify food (cutting into small pieces, pureeing), Prolong meal times, Avoid hard texture foods, Chew excessively, Turn away tablets/pills [61]. As already mentioned by Dr. Gröchenig, linear furrows, concentric rings (trachealization, ringed esophagus, cat esophagus), white exudates, decreased vasculature in the esophageal mucosa, esophageal strictures, a narrow-caliber esophagus, increased mucosal vulnerability and mucosal edema are characteristic, but not specific findings in eosinophilic esophagitis [22].

Management of eosinophilic esophagitis includes empiric elimination diet, pharmacotherapy and endoscopic dilatation of strictures. Different types of diet therapy including elemental diet, allergy testing-based diet and empiric elimination diet have been tested in patients with eosinophilic esophagitis. Since several approaches have turned out to lack compliance for long-term use, and data reported that the skin prick test predicted only 13% of foods associated with eosinophilic esophagitis, an empiric elimination diet in which the most common allergens are excluded is currently recommended for adults as a more practical method [16, 62]. A recent meta-analysis found histological remission in 70% of patients on the six-food group elimination diet (wheat, milk, eggs, nuts, soy, seafood) and in 50% of patients on the four-food group elimination diet (dairy, eggs, legumes, wheat) [63]. Thus, empiric elimination diet may be a useful therapeutic approach and may allow reduction or discontinuation of medications in patients with eosinophilic esophagitis.

A significant number of patients with eosinophilic esophagitis are on treatment with PPIs with at least 30% exhibiting both symptomatic and histological improvement [64]. This is because eosinophilic inflammation may also occur as a consequence of GERD suggesting another disease entity than eosinophilic esophagitis called proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE). Although the underlying mechanism of PPI-REE is still unclear, it is suggested that PPIs block permeation of the causal allergens from the esophageal lumen to the subepithelium by curing the acid damage [65, 66] and that they may reduce eosinophilic inflammation by suppressing Th2-associated cytokine or gene expression independently of the gastric acid inhibitory effect [67, 68]. Thus, symptomatic and histological resolution of esophageal eosinophilia by PPIs does not necessarily indicate the existence of GERD [16]. Besides PPI therapy, topical therapy by swallowed inhaled (into the pharynx) corticosteroids (1–2 mg budesonide twice daily, a standard treatment for asthma) is applied for eosinophilic esophagitis [16]. Recently, budesonide has also been available as orodispensible tablets and suspension for the treatment of this condition [69, 70]. Studies have demonstrated that topical steroid therapy can lead to histological remission in 15–94%, and to symptomatic remission in 30–97% of patients [71]. A discrepancy between symptomatic and histological remission may be attributable to the limited efficacy of steroid therapy on fibrostenotic changes in the subepithelium [72, 73]. Dilatation therapy is recommended for symptomatic patients with esophageal strictures or narrowing despite medical therapy [16] but must be used with great caution and only by experienced physicians.

New therapeutic approaches with antibodies against IL‑5, IL‑4 or IL-13, which have been designed to target specific immune response pathways associated with eosinophilic esophagitis are currently not recommended in the guidelines of the American Gastroenterological Association Institute and the Joint Task Force on Allergy-Immunology Practice Parameters [74].

Dr. A.J. Eherer:
After the diagnosis of eosinophilic esophagitis had been established in the discussed patient, he was treated with topical steroids and a modified elimination diet, which led to symptomatic and histological remission. However, surveillance endoscopy showed that the crepe paper-like esophagus and its increased vulnerability persisted even when he was asymptomatic on steroid therapy. Rarely, these changes may on instrumentation lead to perforation of the esophagus with the consequent need for esophagectomy [75]. Endoscopists should always be aware of this increased vulnerability when performing surveillance esophagoscopy or dilatation of esophageal strictures in patients with eosinophilic esophagitis.

Dr. G.J. Krejs:
First described in the 1990s by Attwood [76] and Straumann [77], eosinophilic esophagitis is now an important diagnosis. Currently, about 30 adult patients are being treated in the outpatient gastroenterology clinic of the Department of Internal Medicine at Graz University Medical Center, but it is expected that this number will increase in the future.

Final diagnosis
Eosinophilic esophagitis



Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements
The authors express their sincere gratitude to Dr. Alina Fakin for language editing of the manuscript.

Funding
Open access funding provided by Medical University of Graz.

Conflict of interest
E. Fabian, H.P. Gröchenig, P.K. Bauer, A.J. Eherer, M. Gugatschka, L. Binder, C. Langner, P. Fickert, and G.J. Krejs declare that they have no competing interests.
==== Refs
References
1. Jameson JL  Fauci AS  Kasper DL  Hauser SL  Longo DL  Loscalzo J   Harrison's principles of internal medicine 2018 20 New York McGraw-Hill 
2. Johnston BT   Oesophageal dysphagia: a stepwise approach to diagnosis and management Lancet Gastroenterol Hepatol 2017 2 8 604 609 28691686 
3. Edwards DA   Discriminative information in the diagnosis of dysphagia J R Coll Physicians Lond 1975 9 3 257 263 1142327 
4. Cook IJ   Diagnostic evaluation of dysphagia Nat Clin Pract Gastroenterol Hepatol 2008 5 7 393 403 18542115 
5. Blonski W  Vela M  Safder A  Hila A  Castell DO   Revised criterion for diagnosis of ineffective esophageal motility is associated with more frequent dysphagia and greater bolus transit abnormalities Am J Gastroenterol 2008 103 3 699 704 18341490 
6. Roman S  Lin Z  Kwiatek MA  Pandolfino JE  Kahrilas PJ   Weak peristalsis in esophageal pressure topography: classification and association with dysphagia Am J Gastroenterol 2011 106 2 349 356 20924368 
7. Ratuapli SK  Crowell MD  DiBaise JK  Vela MF  Ramirez FC  Burdick GE  Lacy BE  Murray JA   Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids Am J Gastroenterol 2015 110 7 979 984 26032150 
8. Shaheen NJ  Hansen RA  Morgan DR  Gangarosa LM  Ringel Y  Thiny MT  Russo MW  Sandler RS   The burden of gastrointestinal and liver diseases, 2006 Am J Gastroenterol 2006 101 9 2128 2138 16848807 
9. Kahrilas PJ   Gastroesophageal reflux disease N Engl J Med 2008 584-12-0411 1707 18923172 
10. Cho SY  Choung RS  Saito YA  Schleck CD  Zinsmeister AR  Locke GR 3rd  Talley NJ   Prevalence and risk factors for dysphagia: a USA community study Neurogastroenterol Motil 2015 27 2 212 219 25376877 
11. Vakil NB  Traxler B  Levine D   Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment Clin Gastroenterol Hepatol 2004 2 8 665 668 15290658 
12. Dakkak M  Hoare RC  Maslin SC  Bennett JR   Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia Gut 1993 34 2 152 155 8432464 
13. Katz PO  Gerson LB  Vela MF   Guidelines for the diagnosis and management of gastroesophageal reflux disease Am J Gastroenterol 2013 108 3 308 328 23419381 
14. Stoschus B  Allescher HD   Drug-induced dysphagia Dysphagia 1993 8 2 154 159 8467724 
15. Gröchenig HP  Tilg H  Vogetseder W   Clinical challenges and images in GI. Pill esophagitis Gastroenterology 2006 131 4 996 1365 17030168 
16. Abe Y  Sasaki Y  Yagi M  Yaoita T  Nishise S  Ueno Y   Diagnosis and treatment of eosinophilic esophagitis in clinical practice Clin J Gastroenterol 2017 10 2 87 102 28247277 
17. Lynch KL  Dhalla S  Chedid V  Ravich WJ  Stein EM  Montgomery EA  Bochner BS  Clarke JO   Gender is a determinative factor in the initial clinical presentation of eosinophilic esophagitis Dis Esophagus 2016 29 2 174 178 25626069 
18. Arias Á  Pérez-Martínez I  Tenías JM  Lucendo AJ   Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies Aliment Pharmacol Ther 2016 43 1 3 15 26510832 
19. Liacouras CA  Furuta GT  Hirano I  Atkins D  Attwood SE  Bonis PA  Burks AW  Chehade M  Collins MH  Dellon ES  Dohil R  Falk GW  Gonsalves N  Gupta SK  Katzka DA  Lucendo AJ  Markowitz JE  Noel RJ  Odze RD  Putnam PE  Richter JE  Romero Y  Ruchelli E  Sampson HA  Schoepfer A  Shaheen NJ  Sicherer SH  Spechler S  Spergel JM  Straumann A  Wershil BK  Rothenberg ME  Aceves SS   Eosinophilic esophagitis: updated consensus recommendations for children and adults J Allergy Clin Immunol 2011 128 1 3 20.e6 21477849 
20. Hirano I   How to approach a patient with eosinophilic esophagitis Gastroenterology 2018 155 3 601 606 30080994 
21. Desai TK  Stecevic V  Chang CH  Goldstein NS  Badizadegan K  Furuta GT   Association of eosinophilic inflammation with esophageal food impaction in adults Gastrointest Endosc 2005 61 795 801 15933677 
22. Kim HP  Vance RB  Shaheen NJ  Dellon ES   The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis Clin Gastroenterol Hepatol 2012 10 9 988 996.e5 22610003 
23. Lucendo AJ  Molina-Infante J  Arias Á  von Arnim U  Bredenoord AJ  Bussmann C  Amil Dias J  Bove M  González-Cervera J  Larsson H  Miehlke S  Papadopoulou A  Rodríguez-Sánchez J  Ravelli A  Ronkainen J  Santander C  Schoepfer AM  Storr MA  Terreehorst I  Straumann A  Attwood SE   Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults United European Gastroenterol J 2017 5 3 335 358 28507746 
24. Aggestrup S  Uddman R  Jensen SL  Sundler F  Schaffalitzky de Muckadell O  Holst JJ  Håkanson R  Ekman R  Sørensen HR   Regulatory peptides in the lower esophageal sphincter of man Regul Pept 1985 10 167 178 2581286 
25. Mearin F  Mourelle M  Guarner F  Salas A  Riveros-Moreno V  Moncada S  Malagelada JR   Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction Eur J Clin Invest 1993 23 724 728 7508398 
26. Clark SB  Rice TW  Tubbs RR  Richter JE  Goldblum JR   The nature of the myenteric infiltrate in achalasia: an immunohistochemical analysis Am J Surg Pathol 2000 24 1153 1158 10935657 
27. Boeckxstaens GE   The lower esophageal sphincter Neurogastroenterol Motil 2005 17 Suppl 1 13 21 15836451 
28. Ates F  Vaezi MF   The pathogenesis and management of achalasia: current status and future directions Gut Liver 2015 9 449 463 26087861 
29. Gockel I  Bohl JR  Eckardt VF  Junginger T   Reduction of interstitial cells of Cajal (ICC) associated with neuronal nitric oxide synthase (n-NOS) in patients with achalasia Am J Gastroenterol 2008 103 4 856 864 18070236 
30. Gockel I  Bohl JR  Doostkam S  Eckardt VF  Junginger T   Spectrum of histopathologic findings in patients with achalasia reflects different etiologies J Gastroenterol Hepatol 2006 21 727 733 16677160 
31. Pandolfino JE  Gawron AJ   Achalasia: a systematic review JAMA 2015 313 1841 1852 25965233 
32. Howard PJ  Maher L  Pryde A  Cameron EW  Heading RC   Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh Gut 1992 33 1011 1015 1398223 
33. Eckardt VF   Clinical presentations and complications of achalasia Gastrointest Endosc Clin N Am 2001 11 281 292 11319062 
34. Fisichella PM  Raz D  Palazzo F  Niponmick I  Patti MG   Clinical, radiological, and manometric profile in 145 patients with untreated achalasia World J Surg 2584-12-0411 1979 18575930 
35. Eckardt VF  Stauf B  Bernhard G   Chest pain in achalasia: patient characteristics and clinical course Gastroenterology 1999 116 1300 1304 10348812 
36. Massey BT  Hogan WJ  Dodds WJ  Dantas RO   Alteration of the upper esophageal sphincter belch reflex in patients with achalasia Gastroenterology 1992 103 1574 1579 1426877 
37. Seeman H  Traube M   Hiccups and achalasia Ann Intern Med 1991 115 711 712 1929039 
38. Spechler SJ  Souza RF  Rosenberg SJ  Ruben RA  Goyal RK   Heartburn in patients with achalasia Gut 1995 37 305 308 7590421 
39. Richter JE   The diagnosis and misdiagnosis of achalasia: it does not have to be so difficult Clin Gastroenterol Hepatol 2011 9 1010 1011 21699819 
40. Spechler SJ  Castell DO   Classification of oesophageal motility abnormalities Gut 2001 49 145 151 11413123 
41. Vaezi MF  Richter JE   Diagnosis and management of achalasia. American College of Gastroenterology Practice Parameter Committee Am J Gastroenterol 1999 94 3406 3412 10606295 
42. Francis DL  Katzka DA   Achalasia: update on the disease and its treatment Gastroenterology 2010 139 369 374 20600038 
43. Kahrilas PJ  Bredenoord AJ  Fox M  Gyawali CP  Roman S  Smout AJPM  Pandolfino JE  International Working Group for Disorders of Gastrointestinal Motility and Function  Expert consensus document: advances in the management of oesophael motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes Nat Rev Gastroenterol Hepatol 2017 14 677 688 28951579 
44. Fabian E  Eherer AJ  Lackner C  Urban C  Smolle-Juettner FM  Krejs GJ   Pseudoachalasia as first manifestation of a malignancy Dig Dis 2019 37 5 347 354 30602160 
45. Yuan SM   Cardiovascular dysphagia—anatomical and clinical implications Folia Morphol (Warsz) 2014 73 2 113 121 24902087 
46. Dellon ES  Liacouras CA  Molina-Infante J  Furuta GT  Spergel JM  Zevit N    Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference Gastroenterology 2018 155 4 1022 1033.e10 30009819 
47. Winter HS  Madara JL  Stafford RJ  Grand RJ  Quinlan JE  Goldman H   Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis Gastroenterology 1982 83 4 818 823 7106512 
48. Parfitt JR  Gregor JC  Suskin NG  Jawa HA  Driman DK   Eosinophilic esophagitis in adults: distinguishing features from gastroesophageal reflux disease: a study of 41 patients Mod Pathol 2006 19 1 90 96 16258505 
49. Krejs GJ  Seefeld U  Braendli HH  Bron BA  Caro G  Schmid P  Blum AL   Gastro-esophageal reflux disease: correlation of subjective symptoms with 7 objective esophageal function tests Acta Hepatogastroenterol 1976 23 130 140 
50. Seefeld U  Krejs GJ  Siebenmann RE  Blum AL   Esophageal histology in gastroesophageal reflux. Morphometric findings in suction biopsies Am J Dig Dis 1977 22 956 964 920705 
51. Bussmann C  Straumann A   Eosinophilic esophagitis: the diagnostic contribution of pathology Pathologe 2013 34 2 110 117 23483314 
52. Dellon ES  Speck O  Woodward K  Covey S  Rusin S  Shaheen NJ  Woosley JT   Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy Mod Pathol 2015 28 3 383 390 25216228 
53. Salek J  Clayton F  Vinson L  Saffari H  Pease LF 3rd  Boynton K  Fang J  Cox K  Peterson KA   Endoscopic appearance and location dictate diagnostic yield of biopsies in eosinophilic oesophagitis Aliment Pharmacol Ther 2015 41 12 1288 1295 25898774 
54. Sherrill JD  Rothenberg ME   Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies J Allergy Clin Immunol 2011 128 1 23 32 21570716 
55. Holvoet S  Blanchard C   Genetic and molecular mechanisms leading to eosinophilic esophagitis Rev Esp Enferm Dig 2014 106 4 276 280 25075658 
56. Comeau MR  Ziegler SF   The influence of TSLP on the allergic response Mucosal Immunol 2010 3 2 138 147 20016474 
57. Rothenberg ME  Mishra A  Brandt EB  Hogan SP   Gastrointestinal eosinophils Immunol Rev 2001 179 139 155 11292017 
58. Blanchard C  Wang N  Stringer KF  Mishra A  Fulkerson PC  Abonia JP  Jameson SC  Kirby C  Konikoff MR  Collins MH  Cohen MB  Akers R  Hogan SP  Assa'ad AH  Putnam PE  Aronow BJ  Rothenberg ME   Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis J Clin Invest 2006 116 2 536 547 16453027 
59. Blanchard C  Stucke EM  Burwinkel K  Caldwell JM  Collins MH  Ahrens A  Buckmeier BK  Jameson SC  Greenberg A  Kaul A  Franciosi JP  Kushner JP  Martin LJ  Putnam PE  Abonia JP  Wells SI  Rothenberg ME   Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis J Immunol 2010 184 7 4033 4041 20208004 
60. Dellon ES  Gibbs WB  Fritchie KJ  Rubinas TC  Wilson LA  Woosley JT  Shaheen NJ   Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease Clin Gastroenterol Hepatol 2009 7 12 1305 1313 19733260 
61. Hirano I  Furuta GT   Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis Gastroenterology 2020 158 840 851 31836530 
62. Gonsalves N  Yang GY  Doerfler B  Ritz S  Ditto AM  Hirano I   Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors Gastroenterology 2012 142 7 1451 1459.e1 22391333 
63. Arias A  González-Cervera J  Tenias JM  Lucendo AJ   Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis Gastroenterology 2014 146 7 1639 1648 24534634 
64. Dellon ES  Speck O  Woodward K  Gebhart JH  Madanick RD  Levinson S  Fritchie KJ  Woosley JT  Shaheen NJ   Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study Am J Gastroenterol 2013 584-12-0411 1860 24145677 
65. Spechler SJ  Genta RM  Souza RF   Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis Am J Gastroenterol 2007 102 6 1301 1306 17531015 
66. van Rhijn BD  Weijenborg PW  Verheij J  van den Bergh Weerman MA  Verseijden C  van den Wijngaard RM  de Jonge WJ  Smout AJ  Bredenoord AJ   Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis Clin Gastroenterol Hepatol 2014 12 11 1815 1823 24657840 
67. Kedika RR  Souza RF  Spechler SJ   Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications Dig Dis Sci 2009 54 11 2312 2317 19714466 
68. Cheng E  Zhang X  Huo X  Yu C  Zhang Q  Wang DH  Spechler SJ  Souza RF   Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD Gut 2013 62 6 824 832 22580413 
69. Lucendo AJ  Miehlke S  Schlag C  Vieth M  von Armin U  Molina-Infante J  Hartmann D  Bredenoord AJ  de Los Rios CC  Schubert S  Brückner S  Madisch A  Hayat J  Tack J  Attwood S  Mueller R  Greinwald R  Schoepfer A  Straumann A   International EOS-1 study group. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial Gastroenterology 2019 157 74 86.e15 30922997 
70. Dellon ES  Katzka DA  Collins MH  Hamdani M  Gupta SK  Hirano I  MP-101-06 Investigators  Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis Gastroenterology 2017 152 776 786.e5 27889574 
71. Dellon ES   Diagnosis and management of eosinophilic esophagitis Clin Gastroenterol Hepatol 2012 10 10 1066 1078 22728382 
72. Straumann A  Conus S  Degen L  Frei C  Bussmann C  Beglinger C  Schoepfer A  Simon HU   Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis Clin Gastroenterol Hepatol 2011 9 5 400 409.e1 21277394 
73. Lucendo AJ  Arias A  De Rezende LC  Yagüe-Compadre JL  Mota-Huertas T  González-Castillo S  Cuesta RA  Tenias JM  Bellón T   Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study J Allergy Clin Immunol 2011 128 5 1037 1046 21880354 
74. Rank MA  Sharaf RN  Furuta GT  Aceves SS  Greenhawt M  Spergel JM  Flack-Ytter YT  Dellon ES   Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Gastroenterology 2020 124 5 424 440.e17 
75. Liguori G  Cortale M  Cimino F  Sozzi M   Circumferential mucosal dissection and esophageal perforation in a patient with eosinophilic esophagitis World J Gastroenterol 2008 14 5 803 804 18205276 
76. Attwood SE  Smyrk TC  Demeester TR  Jones JB   Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome Dig Dis Sci 1993 38 1 109 116 8420741 
77. Straumann A  Spichtin HP  Bernoulli R  Loosli J  Vögtlin J   Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings Schweiz Med Wochenschr 1994 584-12-0411 1429 7939509


{'source': 'PubMedDataset'}